Z. Sztupinszki

The paper identifies DDR biomarkers and ploidy abnormalities in GEA that predict sensitivity to DDR inhibitors and premalignant progression.

This paper identifies NER deficiency as a targetable vulnerability in ccRCC, showing that 10% of patients may respond to irofulven based on mutational signatures and PTGR1 expression.

This study identifies HR and NER deficiencies in gastric and esophageal adenocarcinomas and shows their responsiveness to platinum chemotherapy and PARP inhibitors.

The paper shows that loss of RNASEH2B makes prostate cancer cells sensitive to PARP inhibitors, but co-deletion with RB1 reduces this sensitivity through BRCA2 upregulation, and ATR inhibition can restore sensitivity.

The paper identifies HRD-associated mutational signatures in lung cancer cases and links them to PARP inhibitor sensitivity and platinum response.

The paper identifies genomic aberration-based molecular signatures to detect homologous recombination deficiency in prostate cancer, finding that 5-8% of cases may benefit from PARP-inhibitor treatment.

The paper compares HRD scores in primary breast cancer tumors and their brain metastases, finding higher HRD in metastases, suggesting potential changes in PARP inhibitor therapy strategies.